Inactive Instrument

News Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	AQ
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	Mar. 25	MT
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo	Mar. 25	AQ
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients	Mar. 12	MT
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease	Mar. 12	AQ
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease	Mar. 12	CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	Mar. 11	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	Mar. 11	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	Mar. 11	MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump	Mar. 11	MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell	Mar. 11	MT
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin	Mar. 11	DJ
Lexicon: Q4 Earnings Snapshot	Mar. 11	AQ
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000	Mar. 11	MT
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update	Mar. 11	AQ
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities	Mar. 11	AQ
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	Mar. 11	AQ
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	Mar. 11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

Summary

Filters